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ABSTRACT Complement receptors 1 and 2 (CR1/2 or CD35/CD21) recognize
complement-opsonized antigens to initiate innate and adaptive immunity, respec-
tively. CD35 stimulates phagocytosis on macrophages and antigen presentation on
follicular dendritic cells (FDCs). CD21 helps activate B cells as part of the B cell core-
ceptor with CD19 and CD81. Differential splicing of transcripts from the mouse Cr2
gene generates isoforms with both shared and unique complement binding capaci-
ties and cell-type expression. In mouse models, genetic depletion of Cr2 causes ei-
ther a delay or complete prevention of prion disease, but the relative importance of
CD35 versus CD21 in promoting prion disease remains unknown. Here we show that
both isoforms act as high-afﬁnity cell surface prion receptors. However, mice lacking
CD21 succumbed to terminal prion disease signiﬁcantly later than mice lacking
CD35 or wild-type and hemizygous mice. CD21-deﬁcient mice contained fewer
splenic prions than CD35 knockout mice early after infection that contributed to de-
layed prion neuroinvasion and terminal disease, despite forming follicular networks
closer to proximal nerves. While we observed no difference in B cell networks, PrPC
expression, or number of follicles, CD21-deﬁcient mice formed more fragmented,
less organized follicular networks with fewer Mfge8-positive FDCs and/or tingible
body macrophages (TBMs) than wild-type or CD35-deﬁcient mice. In toto, these
data demonstrate a more prominent role for CD21 for proper follicular development
and organization leading to more efﬁcient lymphoid prion replication and expedited
prion disease than in mice expressing the CD35 isoform.
IMPORTANCE Mammalian prion diseases are caused by prions, unique infectious
agents composed primarily, if not solely, of a pathologic, misfolded form of a normal
host protein, the cellular prion protein (PrPC). Prions replicate without a genetic
blueprint, but rather contact PrPC and coerce it to misfold into more prions, which
cause neurodegeneration akin to other protein-misfolding diseases like Alzheimer’s
disease. A single gene produces two alternatively spliced mRNA transcripts that en-
code mouse complement receptors CD21/35, which promote efﬁcient prion replica-
tion in the lymphoid system and eventual movement to the brain. Here we show
that CD21/35 are high-afﬁnity prion receptors, but mice expressing only CD21 die
from prion disease sooner than CD35-expressing mice, which contain less prions
early after infection and exhibit delayed terminal disease, likely due to their less or-
ganized splenic follicles. Thus, CD21 appears to be more important for deﬁning
splenic architecture that inﬂuences prion pathogenesis.
KEYWORDS complement receptors, prions, spleen
Received 20 October 2017 Accepted 30
October 2017 Published 22 November 2017
Citation Kane SJ, Swanson E, Gordon EO,
Rocha S, Bender HR, Donius LR, Aguzzi A,
Hannan JP, Zabel MD. 2017. Relative impact of
complement receptors CD21/35 (Cr2/1) on
scrapie pathogenesis in mice. mSphere 2:
e00493-17. https://doi.org/10.1128/
mSphereDirect.00493-17.
Editor Michael J. Imperiale, University of
Michigan—Ann Arbor
Copyright © 2017 Kane et al. This is an open-
access article distributed under the terms of
the Creative Commons Attribution 4.0
International license.
Address correspondence to Mark D. Zabel,
mark.zabel@colostate.edu.
This work is dedicated to the memory of John
H. Weis.
Solicited external reviewers: Neil Mabbott,
University of Edinburgh; Motohiro Horiuchi,
Hokkaido University.
This paper was submitted via the
mSphereDirect™ pathway.
CD21 organizes splenic follicles AND
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Mammalian prion diseases are caused by prions, unique infectious agents thoughtto be composed primarily, if not solely, of PrPSc, a pathologic, misfolded form of
a normal host protein, the cellular prion protein (PrPC). The prion and/or PrPSc, ﬁrst
identiﬁed in the sheep prion disease scrapie (1), replicates without a genetic blueprint,
but rather contacts PrPC and coerces it to misfold into more PrPSc. Prions cause
neurodegeneration akin to other protein-misfolding diseases like Alzheimer’s disease.
The complement system consists of over 30 soluble and cell-surface proteins which
serve three main functions: (i) to opsonize extracellular pathogens to trigger phago-
cytosis, (ii) to create the membrane attack complex (MAC) on pathogen cell surfaces to
provoke cell lysis, and (iii) to reduce the threshold for B cell activation upon simulta-
neous engagement of B cell receptor and complement receptor 2. While complement
activation involves a largely nonspeciﬁc recognition of proteins and lipids, it links
the fast-acting innate immune system with the highly speciﬁc, long-term, memory-
inducing, adaptive immune system. During peripheral prion infection, complement
facilitates the early spread and propagation of PrPSc to and within the lymphoreticular
system (LRS). Mice lacking complement proteins C3, C4, C1q, and CD21/35 exhibit
delayed PrPSc accumulation and prion disease onset (2–4). Interestingly, in a mouse
model of chronic wasting disease, genetic depletion of complement receptors CD21/35
(5) completely protected mice from infection, whereas depletion of the receptors’
ligand, C3, delayed but did not entirely prevent disease (6). These data strongly suggest
CD21 or -35 impacts disease independently of its natural ligand, C3.
Murine CD21/35 (CR2/1) arise from differentially splicing Cr2 transcripts (7). Both
transcripts share the ﬁrst exon encoding the signal sequence, and alternative splicing
to exon 7 and 2 results in CD21 and CD35 transcripts, respectively. Both CD21 and CD35
are primarily comprised of short consensus repeats (SCRs), compact repeating -sheet
domains, each approximately 60 amino acids in size and held in a coiled-coil conﬁg-
uration by two disulﬁde bonds. CD21/35 bind ligands via their SCR domains (Fig. 1A).
CD21 contains 15 SCRs and recognizes C3 cleavage products, and CD35 contains an
additional 6 N-terminal SCRs (Fig. 1) which also bind C4 cleavage products (7–9).
Recently, transgenic mice were generated in which either CD21 (10) or CD35 (11)
expression was eliminated.
Human CD21 binds to all its major ligands, iC3b, C3d, C3dg, CD23, and Epstein Barr
gp350/220, using the ﬁrst two SCRs, although the interaction between CD21 and CD23
additionally involves SCRs 5 to 8 (12, 13). On the other hand, human CD35 primarily
binds to the complement C3b and C4b cleavage products and also to C1q (14). Some
cells express both complement receptors, whereas others express only one or the
FIG 1 Illustration of splice variants CD35 and CD21. (A) Boxes show exons (subscript number) encoding
CD21/35 elements (regular case). Murine Cr2 encodes 25 exons, and CD21 and CD35 share exon 1 (SS1).
Transcripts encoding CD21 splice exon 1 to exon 7, whereas CD35 includes intervening exons. (B) CD21
and CD35 both contain extracellular short consensus repeats, a transmembrane domain, and a short
cytoplasmic tail. However, CD35 contains an additional 6 N-terminal SCRs. Shared sequences and
structures are indicated in purple, and red indicates components unique to CD35. SS, signal sequence;
CT, cytoplasmic tail.
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other. Human CD35 expression serves to clear immune complexes by providing a
phagocytic signal for macrophages (15) and neutrophils (16). CD21 forms the B cell
coreceptor (BCCR) with CD19 and CD81 on B cells that provides a costimulatory signal
to reduce the activation threshold upon engagement of B cell receptor with its speciﬁc
antigen (17–19).
CD21/35 have been shown to facilitate prion infection administered peripherally
(3–5), but the relative importance of each isoform remained unknown. Here we show
that while both CD21 and CD35 bind PrPSc with high afﬁnity, mice lacking CD21 form
PrPSc-replicating follicular networks closer to proximal splenic nerves, replicate PrPSc
more slowly, and resist prion disease longer than mice lacking CD35. Follicular networks
in CD21- and CD21/35-deﬁcient mice appeared more fragmented and less organized
and contained fewer Mfge8-positive follicular dendritic cells (FDCs) and/or tingible
body macrophages (TBMs) than wild-type (WT) and CD35-deﬁcient mice, which could
explain impaired prion pathogenesis in these mice.
RESULTS
CD21 and CD35 both bind PrPSc. Previous reports indicate a crucial role for
CD21/35 in prion disease, but whether this role can be attributed to direct interactions
of CD21/35 with PrPSc remained unknown. To address this possibility, we performed a
previously published protocol to remove soluble PrPC and highly enrich insoluble PrPSc
from infected hamster brains (20–22). We then tested whether PrPSc interacts with
puriﬁed full-length CD21 or truncated CD21 containing either SCRs 1 and 2 or SCRs 1
to 6. All of these forms of CD21 bound to PrPSc with similar binding kinetics (Fig. 2A).
Monoclonal antibody (MAb) 171, which binds and prevents CD21 binding to its
endogenous ligands at SCRs 1 and 2 (23–25), inhibited, but did not eliminate, the
interaction between CD21 and PrPSc (Fig. 2B), the dissociation constant (Kd) of which we
FIG 2 CD21 and CD35 both bind PrPSc. PrPSc was enriched from elk brain infected with chronic wasting
disease as previously described (21, 22). (A) Equimolar full-length CD21 or protein containing the ﬁrst two
or ﬁrst six SCRs on CD21 bound PrPSc. (B) Addition of inhibitory monoclonal antibody 171 (iMAb 171)
partially reduced the interaction. (C) Kinetic analysis revealed a Kd of 16 nM between full-length CD21 and
PrPSc. Colored traces denote nanomolar ligand concentrations.
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estimate to be 16 nM (Fig. 2C). These data suggest CD21/35 partially bind PrPSc at its
ﬁrst two SCRs, but may also bind PrPSc at additional SCRs. Alternatively, the prion
binding site on CD21 may overlap the MAb 171 binding site, but CD21 binds PrPSc with
higher afﬁnity than MAb 171.
To explore this further, we used paramagnetic beads coated with the anti-CD21/35
MAb 7G6, which blocks C3d binding at CD21 SCRs 1 and 2 (SCRs 7 and 8 on CD35) (26,
27), to immunoprecipitate CD21/35 from spleen homogenates from prion-infected
wild-type and various complement-deﬁcient mice (Fig. 3A) and found that PrPSc
coprecipitated with CD21/35 from spleens of all mice except control CD21/35/ mice
(Fig. 3B). We also used beads coated with CD21/35 from uninfected C3/4/ mice to
precipitate PrPSc from prion-infected brain homogenate (Fig. 3C and D). Preincubation
of CD21/35-coated beads with a cocktail of CD21 Abs, or PrPSc with plasminogen, which
speciﬁcally binds PrPSc (28), abrogated CD21/35-PrPSc coimmunoprecipitation; irrele-
vant IgG antibodies (Abs), as control competitors, did not (Fig. 3C and D). Conversely,
plasminogen-linked beads used to capture PrPSc (Fig. 3E) effectively precipitated
CD21/35 from uninfected C3/4/ spleen homogenate (Fig. 3F). Excess plasminogen,
but not anti-PrP or irrelevant Abs (Fig. 3E), incubated with PrPSc-coated beads, suc-
cessfully competed for CD21/35 binding (Fig. 3F). Anti-CD35 8C12 Ab also failed to
compete for CD21/35 binding. Only a cocktail of anti-CD21/35 Abs successfully com-
peted against PrPSc binding CD21/35, conﬁrming that CD21/35 does not bind PrPSc
exclusively to the SCRs that bind its endogenous ligands.
sCD21 pretreatment inhibits prion infection and replication in vitro. Identiﬁca-
tion of CD21 or -35 as a high-afﬁnity prion receptor led us to question whether soluble
CD21 (sCD21) could exert a dominant-negative effect to interfere with prion infection.
Pretreatment of RML5-infected brain homogenate with CD21 led to decreased infection
of and prion replication by highly susceptible N2a neuroblastoma cells compared to
N2a cells infected with phosphate-buffered saline (PBS)-treated RML5 (Fig. 4).
CD21 inﬂuences early splenic PrPSc accumulation and terminal prion disease
onset. We previously showed that CD21/35 expedited early splenic prion accumula-
tion, neuroinvasion, and terminal prion disease (3, 5). To determine if one isoform
preferentially facilitates this early pathogenesis, we inoculated mice with RML5 prions
and assessed PrPSc loads in spleen at 30 days postinfection (dpi). Mice deﬁcient in CD21
accumulated less PrPSc in their spleen than CD35-deﬁcient mice (Fig. 5; P 0.0459). We
also monitored time to terminal prion disease in these mice to ascertain whether splice
variant CD35 or CD21 promotes disease onset. We found that CD21-deﬁcient mice
resisted disease signiﬁcantly longer than wild-type, CD35-deﬁcient, or hemizygous mice
(Fig. 6; Table 1), although the levels of PrPSc accumulation in their brains at terminal
disease appeared similar (Fig. 6B). We detected no difference by ﬂuorescence-activated
cell sorting (FACS) in the number of PrPC-positive brain cells or splenocytes or the
amount of PrPC those cells express to account for the differences in prion disease
kinetics we observed (Fig. 6C).
CD21 alters CD19 expression and follicular networks. Previous reports indicate
that lack of CD21/35 leads to increased expression of another member of the BCCR,
CD19 (29, 30). B cells from CD21/35-deﬁcient mice express 33 to 49% more CD19 than
those from CD21/35-sufﬁcient mice. Additionally, changes in CD19 expression have
been shown to impact prion disease. CD19-deﬁcient mice exhibit accelerated prion
neuroinvasion, most likely due to their forming FDC networks that replicate PrPSc in
spleens closer to adjacent nerve ﬁbers (31). To determine whether CD21/35 could be
indirectly affecting prion pathogenesis by altering CD19 expression and/or function, we
ﬁrst investigated CD19 expression on CD21- and CD35-deﬁcient mice. Flow cytometry
revealed a signiﬁcant 38% increase of CD19 on B cells from CD21-deﬁcient mice
compared to wild-type or CD35-deﬁcient mice (Fig. 7). Since CD19’s absence results in
FDC networks closer to proximal nerves, we investigated whether CD19 upregulation
positions FDC networks farther from them. We found that, like CD19-deﬁcient mice,
CD21- and CD21/35-deﬁcient mice also contain splenic follicles positioned closer to
Kane et al.
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FIG 3 CD21/35 directly associates with PrPSc. (A and B) CD21/35 coprecipitates with PrPSc with or without its endogenous
complement ligands. (A) 7G6-coupled beads were incubated with C3/4/, C1q/ or CD21/35/ infected spleen
homogenates, washed, and probed for PrPSc. (B) Beads coated with CD21/35 precipitated PrPSc from infected spleens of
all genotypes except CD21/35/ controls. Markers to the left of the blot indicate molecular mass in kilodaltons. IP,
immunoprecipitation; PK, protease K. (C to F) CD21/35 can capture PrPSc in vitro. (C) Uninfected C3/4/ spleen-derived
CD21/35-coated beads were preincubated with a cocktail of anti-CD21/35 or rat IgG2a Abs. PrPSc was preincubated with
20 g plasminogen. (D) Excess plasminogen or the CD21/35 Ab cocktail, but not control Abs, signiﬁcantly decreased
capture. Ten percent input spleen homogenate and PrPSc were used as controls. Markers to the left of the blot indicate
the same molecular mass in kilodaltons as in panel B. (E) Plasminogen-coated beads were incubated with 100 g RML5,
washed, and incubated with uninfected spleen homogenate from C3/4/ mice. Spleen homogenate was preincubated
with 20 g anti-CD21/35 8C12, anti-PrP 6H4 Ab, anti-CD21/35 Ab cocktail, or IgG control Ab. (F) Plasminogen-enriched
PrPSc captured CD21/35, and the CD21/35 Ab cocktail and plasminogen, but not 8C12 alone or the IgG control, signiﬁcantly
decreased capture. The anti-PrP MAb 6H4 competed to a lesser degree. Ten percent input spleen homogenate and PrPSc
were used as controls. Markers to the left of the blot indicate the same molecular mass in kilodaltons as in panel B.
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proximal nerves than wild-type or CD35-deﬁcient mice (Fig. 8A and B). Thus, despite
reduced neurofollicular distances in their spleens, CD21-deﬁcient mice still survived
prion infection longer than wild-type or CD35-deﬁcient mice, coinciding with the
reduced splenic PrPSc replication we observed early after infection. Efﬁcient prion
replication in lymphoid follicles requires intact, organized follicular networks where
PrPC and CD21/35-expressing FDCs and B cells can efﬁciently capture and replicate
PrPSc. We observed more fragmented, less organized follicular networks composed of
signiﬁcantly less FDCs and TBMs in spleens from CD21- and CD21/35-deﬁcient mice
than CD35-deﬁcient and wild-type mice (Fig. 8A and C), which could explain their
differential prion replication. We observed little or no differences in B cell architecture
and PrPC expression, save slightly increased marginal zone B cells in CD21/35/
spleens (Fig. 9) as previously described (30).
DISCUSSION
Attempts to ascertain CD21/35 functions previously relied on Cr2 genetic manipu-
lations that render mice deﬁcient in both CD21 and CD35. However, Donius et al. (10,
11) generated mice that express one splice variant or the other, allowing researchers to
assess the function and relative importance of each splice variant to cells that express
them. For example, CD35 on macrophages and neutrophils is generally thought to
promote phagocytosis and immune complex clearance, whereas CD21 on follicular
dendritic (FDC) and B cells is thought to enhance antigen presentation and adaptive
immune responses, respectively. These mice offer the ability to challenge or conﬁrm
these proposed roles.
The role of complement receptors in prion disease is well established. Mice deﬁcient
FIG 4 Soluble CD21 inhibits prion infection in vitro. RML5-infected brain homogenate (0.33%) was
pretreated with either PBS or CD21 (5-g/ml ﬁnal concentration) prior to infecting N2a cells. (A) After
culture of cells infected with treated prions for 4 days, cells were harvested and analyzed for PrPSc and
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as a loading control. (B) Cells infected with
CD21-pretreated inoculum contained signiﬁcantly lower PrPSc densitometric signal than PBS-treated
controls (unpaired one-way t test, P  0.0182). Markers to the left of the blot indicate the 25-kDa
molecular mass.
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in CD21/35 exhibit delayed clinical disease when challenged with mouse-adapted
scrapie prions (3) or an elk-derived isolate of chronic wasting disease prions (5). These
seminal papers highlight a crucial role in CD21/35 in prion disease, although the
relative importance of each splice variant remained unknown.
Here we show that both variants derived from Cr2 transcripts can biochemically
interact with PrPSc (Fig. 2). This ﬁnding supports the previous in vivo data and suggests
CD21/35 are cell-surface prion receptors. Interestingly, in the mouse model of chronic
wasting disease, C3-deﬁcient mice eventually succumbed to terminal prion disease,
whereas CD21/35-deﬁcient mice did not (5, 6). Our current data support the idea that
CD21/35 impacts prion disease by directly interacting with PrPSc independent of its
endogenous complement ligands. These data suggest that CD21/35 binds PrPSc in a
less-site-speciﬁc manner than its endogenous ligands, but do not exclude the possi-
bility of CD21/35 binding to C3 and C4 cleavage products bound PrPSc. CD21/35 likely
exerts its effects along with C3/4 opsonization, although perhaps not crucially, nor do
our current data exclude the remote possibility that other proteins mediate this
interaction.
We also conﬁrmed CD21/35 as prion receptors and that soluble CD21 (sCD21) can
act in a dominant-negative fashion to inhibit prion replication and infection of N2a cells
in cell culture. Cells infected with prions pretreated with CD21 appeared to contain less
total PrP signal (without protease K [PK] digestion) than PBS-treated controls. Prion
replication likely increased the PrPSc signal that contributed to the higher total PrP
signal in PBS-treated samples, but we cannot deﬁnitively discount the possibility that
CD21 caused a reduction of PrPC. In either case, these data suggest sCD21 could serve
as a therapeutic, and we are currently exploring the use of sCD21 or soluble SCRs as
small, prion-inhibitory molecules in vivo.
CD21/35-expressing B cells and FDCs are known to impact prion disease. B cells
likely promote prion trafﬁcking more so than replication, because deletion of prnp
speciﬁcally in B cells did not inhibit prion disease (32, 33). Thus, B cells promote prion
FIG 5 CD21 promotes splenic accumulation at 30 dpi. Mice deﬁcient in either CD35 or CD21 were
inoculated i.p. with RML5 prions and sacriﬁced at 30 dpi. (A) Spleen homogenates (10% [wt/vol]) were
probed for PrPSc and/or subjected to serial rounds of PMCA and analyzed for PrPSc via Western blotting.
The marker to the left of the blot indicates the 25-kDa molecular mass. (B) PMCA revealed that spleens
from CD21-deﬁcient mice contained signiﬁcantly less PrPSc than those from CD35-deﬁcient mice (P 
0.0459, one-tailed t test).
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disease independent of PrPC expression, and the data presented here support that
hypothesis. We have previously shown that optimal prion trafﬁcking to, capture by, and
replication in lymphoid follicles require CD21/35 expression on FDCs and B cells (3, 5).
We propose CD21 acts as the prion receptor on B cells that mediates these facets of
prion pathogenesis.
FDCs previously have been shown to be perhaps the most important immune cell
type for peripheral prion pathogenesis. They express the most PrPC of any immune cell,
and ablating them or manipulating follicular networks impacts peripherally initiated
FIG 6 CD21-deﬁcient mice survived terminal prion disease longer than wild-type, hemizygous, or
CD35-deﬁcient mice. Mice (n  6 per genotype) were inoculated i.p. with a single high dose (106 LD50
units) of RML5 prions and monitored for the onset of terminal disease. (A) CD21-deﬁcient mice lived
signiﬁcantly longer than all other genotypes, which did not signiﬁcantly differ from each other. (B)
Representative Western blot conﬁrming that all mice contained PrPSc at the onset of terminal disease.
The marker to the left of the blot indicates the 25-kDa molecular mass. (C) We detected no difference in
the number of PrP brain cells or splenocytes or the amount of PrPC they express by FACS. Error bars do
not extend beyond symbols.
TABLE 1 Terminal prion disease progression
Genotypea Incidenceb Mean dpi  SDc
WT (C57BL/6) 17/17 212  12d
Hemizygous 8/8 215  10
CD35/ 6/6 212  14
CD21/ 6/6 229  11e
CD21/35/ 10/10 255  26d,e
aMice were inoculated i.p. with 106 LD50 units of RML5 prions.
bNumber of terminally ill mice/number of mice inoculated.
cDays postinoculation  standard deviation.
dData from our previous study (2) are included in these analyses.
eP  0.05 compared to all other groups.
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prion disease more than any other cell type (34, 35). However, B cells help orchestrate
follicular development by providing lymphotoxin  and  as maturation and mainte-
nance signals to FDCs (35, 36). Loss of the BCCR member CD19 alters follicular
development, moving FDC networks closer to proximal nerves and expediting neuro-
invasion and terminal prion disease (31). We observed the same phenomenon in CD21-
and CD21/35-deﬁcient and, to a lesser extent, CD35-deﬁcient spleens. However, despite
reduced neurofollicular distances in CD21-deﬁcient mice, they still survived prion
disease signiﬁcantly longer than wild-type and CD35-deﬁcient mice. CD21-deﬁcient
mice express full-length CD35 and a slightly truncated form missing SCRs 5 and 6 (11),
which may not bind prions as efﬁciently. However, CD35-deﬁcient mice also lack these
and another four SCRs, and our SPR and coimmunoprecipitation data showing prions
binding multiple SCRs argue against this explanation. CD21- and CD35-deﬁcient mice
develop normal splenic architecture, express normal populations and proportions of B
cells, and express normal levels of PrPC. CD21/35 mice do express slightly expanded
marginal zone B cells (30), but one would expect that expansion to result in enhanced
prion replication, if any effect at all. We did observe fragmented, less organized follicles
that contained less Mfge8-positive FDCs and TBMs in spleens from CD21- and
CD21/35-deﬁcient mice that we conclude impaired early prion capture, replication, and
eventual neuroinvasion. CD21 forms the BCCR with CD19 and CD81 and appears to be
the more important isoform for proper follicular development. Along with altered FDC
networks observed in CD19-deﬁcient mice, these data strongly promote the BCCR as an
important signaling complex in developing normal follicular architecture. We conclude
that proper follicular development and organization require CD21, leading to more
FIG 7 CD21 deﬁciency increases CD19 expression. (A) Flow cytometry revealed an increase in CD19
expression on B cells from CD21-deﬁcient mice compared to CD35-deﬁcient and wild-type mice. (B) CD19
MFI was statistically signiﬁcantly higher on CD21-deﬁcient B cells (**, P  0.01).
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efﬁcient lymphoid prion replication and expedited neuroinvasion in CD21-expressing
mice than in mice expressing the CD35 isoform.
Known CD35 functions include phagocytosis and clearance of opsonized pathogens
and immune complexes on neutrophils and macrophages (15, 16). CD35 can also
biochemically interact with PrPSc, but likely promotes its phagocytosis by and destruc-
tion and/or sequestration within macrophages, the only cell type known to help resolve
prion infection (37). CD21/35 likely act as PrPSc receptors on FDCs, which act as efﬁcient
PrPSc bioreactors in the lymphoreticular system. CD21, however, engages C3d/g op-
sonized pathogens and provides a costimulatory signal when a mature, naive B cell
encounters its speciﬁc antigen. Therefore, in conjunction with previous reports, our
FIG 8 CD21/35 affects follicular development. (A) Immunoﬂuorescent histology of 5-m frozen spleen
sections stained with anti-Mfge8 Ab to identify follicles (FDCs and TBMs [green]) and anti-tyrosine
hydroxylase (anti-TH) Ab to identify nerve ﬁbers (red). Proximal nerves appeared closer to follicular
networks in spleens from CD21-, CD35-, and CD21/35-deﬁcient mice than wild-type C57BL/6 mice.
Follicular networks appeared more fragmented and less organized, with fewer Mfge8-positive FDCs and
TBMs forming networks in CD21- and CD21/35-deﬁcient spleens than in CD35-deﬁcient or wild-type
spleens. (B) Mean neurofollicular distances were shortened in the absence of CD21 (n  95), CD35 (n 
92), or CD21/35 (n 94), with no statistically signiﬁcant difference between distances observed in CD21-
and CD21/35-deﬁcient spleens. Distances measured in C57BL/6 spleens (n  57) were signiﬁcantly
different from those of all other groups. ****, P  0.0001; **, P  0.01. (C) CD21 (n  54)- and CD21/35
(n  52)-deﬁcient splenic follicles contained signiﬁcantly fewer Mfge8-positive FDCs and TBMs than
CD35-deﬁcient (n  50) and C57BL/6 (n  54) follicles. **, P  0.01, and ***, P  0.0001, compared to
CD21- and CD21/35-deﬁcient follicles.
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data clarify the role of B cells in prion disease, including promotion of optimal follicular
development mediated by the BCCR and interaction of CD21/35 with PrPSc.
MATERIALS AND METHODS
Mice. All mice were bred and maintained at Lab Animal Resources, accredited by the Association for
Assessment and Accreditation of Lab Animal Care International and approved on 14 January 2016 by the
Institutional Animal Care and Use Committee at Colorado State University (protocol ID 09-1580A). CD21
(CR2)- or CD35 (CR1)-speciﬁc knockout mice on the C57BL/6 background were generated and charac-
terized as previously described (10, 11). We crossed the individual knockout mice to achieve hemizy-
gosity.
Mouse inoculations. Age- and sex-matched mice (n 6 per genotype) ranging in age from 6 weeks
to 1 year intraperitoneally (i.p.) received 100 l of approximately 106 50% lethal dose (LD50) units of
mouse-adapted scrapie strain RML5 prions (38).
Clinical sign scoring. Mice were monitored daily and sacriﬁced at the onset of terminal disease or
speciﬁed time points. We employed a scoring system to assess the severity of disease, including: tail
rigidity (0 to 2), akinesia (0 to 4), ataxia (0 to 4), tremors (0 to 4), and weight loss (0 to 2). Mice that scored
above 10 were euthanized via CO2 inhalation, replacing 20% of air per minute to effect.
Tissue collection and analysis. After euthanasia, the following samples were collected and frozen
or ﬁxed in 4% formaldehyde in PBS: serum, spleen (half ﬁxed, half frozen), kidneys (one ﬁxed, one frozen),
tail clip, and brain (half ﬁxed, half frozen). We assessed the presence of PrPSc in 10% (wt/vol) homogenate
after protease K (Roche) digestion (10 g/ml for spleen and 50 g/ml for brain) and Western blotting
using anti-PrP monoclonal antibody (Ab) BAR 224 (Cayman Chemical) conjugated to horseradish
peroxidase (HRP). Blots were developed using chemiluminescent substrates hydrogen peroxide and
luminol for 5 min at room temperature and visualized using a GE digital imager and ImageQuant
software. Tissues negative for PrPSc on Western blots were subjected to serial protein misfolding cyclic
ampliﬁcation (PMCA [39]). Brieﬂy, we used 10% normal brain homogenate (NBH) in PMCA buffer (PBS, 1%
Triton X-100, 4 mM EDTA, 150 mM NaCl) from PrPC-overexpressing transgenic mice of strain Tga20 (40)
as the substrate for ampliﬁcation of previously undetectable PrPSc. Twenty-ﬁve microliters of NBH and
25 l 10% sample homogenate were sonicated for 40 s at ~150 W, followed by a 30-min incubation,
which was repeated for 24 h (one round). Serial rounds were performed similarly, transferring 25 l of
the previous round’s sample to 25 l of fresh NBH. Each biological sample was run in at least technical
duplicates, and round to positivity was determined by protease K (PK) digestion and Western blotting.
Relative PMCA units were assigned as previously described (41).
FIG 9 Normal B cell architecture and PrPC expression in mice deﬁcient in CD21, CD35, or both.
Immunoﬂuorescent staining of splenic follicles for PrPC (red) and B220 (green) showing relatively normal
B cell numbers and structure and comparable PrPC expression in follicles from wild-type (C57BL/6),
CD35/, CD21/, and CD21/35/ spleens. We observed slightly expanded marginal zone B cells in
CD21/35/ spleens, but total B cell numbers were not signiﬁcantly altered. Scale bar, 100 m.
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PrPSc enrichment. PrPSc was enriched from infected brain as previously described (20, 21). Brieﬂy, a
brain from an elk infected with chronic wasting disease (E2) was homogenized in PBS to a 10% (wt/vol)
concentration. Sucrose (1.2 M) was added to 10 ml of clariﬁed tissue to a ﬁnal concentration of 165.5 mM,
and samples were ultracentrifuged (100,000  g) for 1 h at 4°C. Pellets were resuspended to a ﬁnal
protein concentration of 5.0 mg/ml in 1 Tris-buffered saline (TBS) containing 2.0% Triton X-100 (TBST)
and incubated on ice for 30 min. Samples were subjected to another round of ultracentrifugation for
20 min at 0°C and washed twice in 1 TBST and twice with 1 TBS. The pellets were then resuspended
in PBS containing 1% Sarkosyl and protease inhibitor cocktail (Roche). Vortexed samples were incubated
on a heated shaker at 37°C for 2 h at 800 rpm. Samples were then gently overlaid onto a cushion of
0.32 M sucrose in PMCA buffer 1 (PMCA buffer without Triton X-100) and ultracentrifuged for 1 h at 4°C,
and supernatants were removed. Pellets were resuspended in 2.3 M NaCl–5% Sarkosyl in PBS, centrifuged
at 13,000  g, washed three times in 50 mM Tris–150 mM NaCl, and either stored dry or suspended in
PBS at 80°C. The presence of PrPSc was conﬁrmed by Western blotting. Lack of complement proteins
in these preparations was conﬁrmed by enzyme-linked immunosorbent assay (ELISA).
Expression of recombinant wild-type CD21 SCR1 to -6 and CD21 SCR1 and -2. The codon-
optimized (Homo sapiens) DNA sequences for human CD21 SCR1 to -6 and CD21 SCR1 and -2 (comprising
residues 21 to 409 and residues 21 to 153, respectively; Uniprot identiﬁer P20023), which had been
subcloned into the pDONR221 entry vector (Life Technologies, Inc.) were purchased from GeneArt. The
engineered sequences additionally contained DNA encoding an Ig kappa chain leader sequence to
facilitate secretion of the target protein, a Gly-Ala-Gly-Ala-Gly-Ala linker region, a hexahistidine (His6)
fusion tag, a second linker region (Asp-Tyr-Asp-Ile-Pro-Thr-Thr), and a tobacco etch virus (TEV) nuclear
inclusion A endopeptidase cleavage site (Glu-Asn-Leu-Tyr-Gln-Gly), all of which are located 5= prime to
the synthetic genes. These sequences were then recombined into a pcDNA3.2/V5-Dest expression vector
using Gateway LR clonase II enzyme mix (Life Technologies, Inc.) according to the manufacturer’s
instructions. The resulting expression constructs were ampliﬁed and transiently transfected into Freestyle
293f cells grown in suspension in an 8% CO2 humidiﬁed environment at 37°C. After 96 h, the cells were
harvested by centrifugation, and the spent medium was collected and passed through a 0.22-m-pore
ﬁlter to remove cellular debris.
CD21 SCR1 to -6 were prepared by diluting spent medium into a 5 buffer containing 0.1 M sodium
phosphate (pH 7.8), 2.5 M NaCl, 0.1 M imidazole (to give a ﬁnal working concentration of 20 mM sodium
phosphate [pH 7.8], 0.5 M NaCl, 20 mM imidazole). The diluted protein was then applied to a 5 ml Histrap
HP column (GE Healthcare, Inc.) using an ÄKTAprime Plus (GE Healthcare, Inc.) liquid chromatography
system and subsequently eluted using a linear imidazole gradient (20 mM to 0.5 M). CD21 SCR1 to -6
were then concentrated at room temperature using a Vivaspin 20 device (Millipore Inc.) and applied to
a HiPrep 16/60 Sephacryl S200 size exclusion column (GE Healthcare, Inc.) that had been equilibrated
with Dulbecco’s phosphate-buffered saline (DPBS) without MgCl2 or CaCl2 (DPBS is 2.7 mM KCl, 1.5 mM
KH2PO4, 138 mM NaCl, 8.1 mM Na2HPO4 [pH 7.4]) using an ÄKTADesign high-pressure liquid chroma-
tography system (GE Healthcare, Inc.). The purity of the resulting puriﬁed recombinant CD21 SCR1 to -6
was assessed by SDS-PAGE.
CD21 SCR1 and -2 were also initially puriﬁed from spent medium by immobilized metal afﬁnity
chromatography in a manner identical to that described for CD21 SCR1 to -6. However, after elution, the
partially puriﬁed CD21 SCR1 and -2 were buffer exchanged into a 1/3 DPBS buffer and applied to a C3d
afﬁnity column, generated by binding glutathione S-transferase (GST)-tagged C3d to a 5-ml GSTrap
column (GE Biosciences). CD21 SCR1 and -2 were eluted using a linear NaCl gradient of 0 to 0.5 M in 1/3
PBS as previously described (42). Any coeluted GST-C3d was removed by manually applying the resulting
solution to a 1-ml GSTrap column. Finally, puriﬁed CD21 SCR1 and -2 were concentrated in a Vivaspin 20
concentration device and assessed by SDS PAGE.
Production of the anti-CR2 iMAb 171. The anti-CR2 inhibitory monoclonal antibody (iMAb) 171 was
obtained from the spent culture medium of hybridoma cells grown in RPMI 1640 supplemented with
2 mM L-glutamine, 100 IU penicillin, 100 g/ml streptomycin, and 10% fetal bovine serum. Abs were
puriﬁed by afﬁnity chromatography using protein G Sepharose 4 Fast Flow resin (GE Healthcare
Biosciences Corp.). Puriﬁed iMAb 171 was then exchanged into PBS and ﬁnally concentrated to give a
stock solution containing 1 mg/ml.
SPR. Highly enriched PrPSc were coupled to CM5 sensor chips outside the instrument after gener-
ating the reference ﬂow cells within the instrument by activation with EDC/NHS [0.2 M 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride and 0.05 M N-hydroxysuccinimide] and deactivation
with ethanolamine three to ﬁve times. The chip was then removed from the instrument and the gold
chip disassembled from the cassette. The entire surface was activated with 100 l of EDC/NHS for 12 min.
A PrPSc pellet was resuspended in 100 l of 10 mM sodium acetate (pH 5.4), sonicated at 37°C for 40 s,
and incubated on the gold chip at room temperature for 1 h. The chip was then brieﬂy rinsed with PBS,
and the remaining active groups were deactivated with ethanolamine for 7 min. Prior to use in
interaction analyses, a startup cycle of 50 mM sodium hydroxide served to remove any nonspeciﬁcally
bound PrPSc from the surface.
All surface plasmon resonance (SPR) experiments involved recombinant human PrP (rPrP) or PrPSc
enriched from infected elk brain as the ligand coated to a CM5 series S sensor chip. Puriﬁed CD21 and
CD21 containing SCR1 and -2 or SCR1 to -6 was buffer exchanged in Amicon ﬁlter devices into 1
running buffer (50 mM Tris HCl, 150 mM NaCl [pH 7.42]). The rPrP-coated chip was kindly provided by
Hae-Eun Kang in the Telling lab. Brieﬂy, ﬂow cells were ﬁrst activated with EDC/NHS for 7 min at
10 l/min. Amine coupling of recombinant cervid or murine PrPC in 10 mM sodium acetate (pH 5.5) was
accomplished by ﬂowing 20 g/ml of ligand over the activated chip for 7 min at 10 l/min. Excess
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activated groups were deactivated with 1 M ethanolamine HCl (pH 8.5) for 7 min at 10 l/min. Reference
ﬂow cells, built-in negative controls for this system, underwent rounds of activation and deactivation
without protein ligand.
Cell culture and in vitro prion infection. N2a mouse neuroblastoma cells were grown in RPMI 1640
medium containing 10% fetal bovine serum and 1% penicillin–streptomycin. RML5-infected brain
homogenate was UV sterilized prior to infection of cells. RML5 was preincubated with PBS or CD21 (SCR1
and -2; 5 g/ml ﬁnal concentration) for 10 to 20 min prior to infecting cells. N2a cells were seeded at
100,000 cells per well in a 12-well plate and infected with 0.3% RML5. Cells were grown at 37°C and 5%
CO2 for 4 days. Wells were rinsed 2 in PBS, and cells were detached from the plate using 5 mM EDTA
in PBS for 10 min. Cell pellets were resuspended in 100 l PMCA buffer containing 1% Triton X-100 and
lysed on ice for 30 min. Lysates were assessed for PrPSc using traditional PK digestion and Western
blotting techniques.
FACS. Fresh brain and spleens were harvested and processed to single-cell suspensions in 3 ml PBS.
Brieﬂy, tissues were passed through 40-m-pore mesh ﬁlters using sterile plungers and cold PBS washes.
Cells were pelleted at 250 g for 5 min at 4°C, and the supernatant was discarded. Red blood cells (RBCs)
were lysed in ACK (ammonium-chloride-potassium) buffer for 5 min, and the remaining cells were
pelleted and washed with FACS buffer (PBS, 1% fetal bovine serum [FBS], 150 mM EDTA). Primary
splenocytes or brain suspensions were blocked in 7% mouse serum and 1:50 Fc block (BD Pharmingen)
for 20 to 60 min on ice. Ab solutions (1:100 ﬁnal) were added to cells and incubated in the dark for 1 h
on ice. Cells were washed by adding 1 ml FACS buffer to existing Ab solution. Cells were pelleted and
resuspended in 1 ml FACS buffer for a total of 3 washes. A 792-l cell suspension was added to 8 l of
100 g/ml propidium iodide (Sigma) immediately prior to data acquisition in a Cyan ﬂow cytometer.
Unstained samples were analyzed ﬁrst to set detector voltage and gating parameters to place the mean
ﬂuorescent intensity of at least 99% of unstained cells in a well-deﬁned peak in the ﬁrst decade of a log
scale. Mean ﬂuorescent intensity (MFI) signals beyond this decade were called positive. MFI as well as
frequency of parent gate values were imported into Excel and/or GraphPad Prism for analysis.
PAA and immunoprecipitations. The PrPSc afﬁnity assay (PAA) was performed as previously
described (28). Sixty micrograms of CD21/35 Ab 7G6 or 7E9 (BD Pharmingen) was incubated with 109
M-270 magnetic epoxy beads (Dynal, Oslo, Norway) in 1 M ammonium sulfate in PBS for 72 h at 4°C with
tilt rotation. Beads were washed with PBS and then blocked overnight at 4°C with 5% bovine serum
albumin (BSA) in PBS, washed, and resuspended in 500 l PBS. Anti-CD21/35 or plasminogen beads were
incubated with 1,000 g infected or uninfected spleen homogenate overnight at 4°C or 100 g RML5 for
90 min at room temperature, respectively. CD21/35- or PrPSc-coated beads were washed and incubated
with 100 g RML or 1,000 g uninfected spleen homogenate, respectively. For competition experiments,
free or plasminogen bead-bound RML5 was incubated overnight at 4°C with 20 g plasminogen, mouse
IgG, or anti-PrP MAb 6H4. Spleen homogenate or immunoprecipitated CD21/35 was incubated overnight
at 4°C with 20 g anti-CD21/35 Ab 7G6 (Pharmingen) or a cocktail of anti-CD21/35 Abs consisting of 7G6,
8C12, 7E9, 8D9 (Pharmingen), and D-19 (Santa Cruz).
Immunoﬂuorescent histology and morphometry of spleen sections. Spleens were removed from
mice of each genotype and ﬂash frozen in OCT medium in liquid nitrogen. Five-micrometer sections were
cut onto glass slides, ﬁxed in ice-cold acetone for 10 min, air dried overnight, and incubated in 1:50
dilution of Fc block (BD Pharmingen) and 10% rat serum in Ultra Cruz blocking reagent (Santa Cruz) for
1 h at room temperature. Samples were then incubated in anti-mouse tyrosine hydroxylase (TH) Ab,
rinsed three times for 5 min with PBS, followed by incubation with CruzFluor 555 (CF555)-conjugated
mouse IgG binding protein (Santa Cruz) to stain splenic nerves. Slides were then rinsed and blocked
again and then incubated with anti-mouse Mfge8 Ab followed by CF488-cojugated mouse IgG binding
protein (Santa Cruz) to stain follicular dendritic cells (FDCs) and tingible body macrophages (TBMs). B
cells were stained with Alexa 488-conjugated anti-B220 Ab (Pharmingen). PrPC was detected using Alexa
650-conjugated BAR 224. Slides were rinsed again and coverslips mounted with ProLong Gold antifade
mounting medium (Life Technologies, Inc.). Splenic follicles were visualized with an Olympus BX-60
ﬂuorescence microscope, and images were captured using a DP-71 charge-coupled diode camera
(Olympus). Neurofollicular distances were measured and cells counted in at least six nonconsecutive
sections from two spleens from two mice of each genotype using a morphometric overlay module in
GraphicConverter (Lemke Software).
Statistical analyses. All statistical analyses were performed using GraphPad Prism software. We used
log rank tests to compare survival curves, Student’s t test to compare PMCA scores, and one-way analyses
of variance (ANOVA) for all other comparisons among genotypes. Data comparisons with P values of
0.05 were considered signiﬁcantly different. Technical duplicates were averaged, and the mean value
of each biological replicate was considered an n value of 1.
ACKNOWLEDGMENTS
National Institutes of Health grants from the National Institute of Neurological
Disorders and Stroke (R01NS056379-02 and F31NS087762) and National Institute of
Allergy and Infectious Diseases (R56AI122273) funded this work.
The content is solely the responsibility of the authors and does not necessarily
represent the ofﬁcial views of the National Institutes of Health.
We thank Mike Holers for sharing CD21 reagents.
Relative Impact of CD21/35 on Scrapie Pathogenesis
November/December 2017 Volume 2 Issue 6 e00493-17 msphere.asm.org 13
 o
n
 D
ecem
ber 28, 2017 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
REFERENCES
1. Barry RA, Prusiner SB. 1986. Monoclonal antibodies to the cellular and
scrapie prion proteins. J Infect Dis 154:518–521. https://doi.org/10.1093/
infdis/154.3.518.
2. Mabbott NA, Bruce ME, Botto M, Walport MJ, Pepys MB. 2001. Temporary
depletion of complement component C3 or genetic deﬁciency of C1q
signiﬁcantly delays onset of scrapie. Nat Med 7:485–487. https://doi.org/
10.1038/86562.
3. Zabel MD, Heikenwalder M, Prinz M, Arrighi I, Schwarz P, Kranich J, von
Teichman A, Haas KM, Zeller N, Tedder TF, Weis JH, Aguzzi A. 2007.
Stromal complement receptor CD21/35 facilitates lymphoid prion colo-
nization and pathogenesis. J Immunol 179:6144–6152. https://doi.org/
10.4049/jimmunol.179.9.6144.
4. Klein MA, Kaeser PS, Schwarz P, Weyd H, Xenarios I, Zinkernagel RM,
Carroll MC, Verbeek JS, Botto M, Walport MJ, Molina H, Kalinke U,
Acha-Orbea H, Aguzzi A. 2001. Complement facilitates early prion patho-
genesis. Nat Med 7:488–492. https://doi.org/10.1038/86567.
5. Michel B, Ferguson A, Johnson T, Bender H, Meyerett-Reid C, Pulford B,
von Teichman A, Seelig D, Weis JH, Telling GC, Aguzzi A, Zabel MD. 2012.
Genetic depletion of complement receptors CD21/35 prevents terminal
prion disease in a mouse model of chronic wasting disease. J Immunol
189:4520–4527. https://doi.org/10.4049/jimmunol.1201579.
6. Michel B, Ferguson A, Johnson T, Bender H, Meyerett-Reid C, Wyckoff AC,
Pulford B, Telling GC, Zabel MD. 2013. Complement protein C3 exacer-
bates prion disease in a mouse model of chronic wasting disease. Int
Immunol 25:697–702. https://doi.org/10.1093/intimm/dxt034.
7. Molina H, Kinoshita T, Inoue K, Carel JC, Holers VM. 1990. A molecular
and immunochemical characterization of mouse CR2. Evidence for a
single gene model of mouse complement receptors 1 and 2. J Immunol
145:2974–2983.
8. Kurtz CB, O’Toole E, Christensen SM, Weis JH. 1990. The murine com-
plement receptor gene family. IV. Alternative splicing of Cr2 gene tran-
scripts predicts two distinct gene products that share homologous
domains with both human CR2 and CR1. J Immunol 144:3581–3591.
9. Fingeroth JD, Heath ME, Ambrosino DM. 1989. Proliferation of resting B
cells is modulated by CR2 and CR1. Immunol Lett 21:291–301. https://
doi.org/10.1016/0165-2478(89)90022-9.
10. Donius LR, Handy JM, Weis JJ, Weis JH. 2013. Optimal germinal center B
cell activation and T-dependent antibody responses require expression
of the mouse complement receptor Cr1. J Immunol 191:434–447.
https://doi.org/10.4049/jimmunol.1203176.
11. Donius LR, Orlando CM, Weis JJ, Weis JH. 2014. Generation of a novel Cr2
gene allele by homologous recombination that abrogates production of
Cr2 but is sufﬁcient for expression of Cr1. Immunobiology 219:53–63.
https://doi.org/10.1016/j.imbio.2013.08.003.
12. Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM. 2010. Biophysical
investigations of complement receptor 2 (CD21 and CR2)-ligand inter-
actions reveal amino acid contacts unique to each receptor-ligand pair.
J Biol Chem 285:27251–27258. https://doi.org/10.1074/jbc.M110.106617.
13. Hannan JP. 2016. The structure-function relationships of complement
receptor type 2 (CR2; CD21). Curr Protein Pept Sci 17:463–487. https://
doi.org/10.2174/1389203717666151201192124.
14. Reilly BD, Makrides SC, Ford PJ, Marsh HC, Mold C. 1994. Quantitative
analysis of C4b dimer binding to distinct sites on the C3b/C4b receptor
(CR1). J Biol Chem 269:7696–7701.
15. Newman SL, Becker S, Halme J. 1985. Phagocytosis by receptors for C3b
(CR1), iC3b (CR3), and IgG (Fc) on human peritoneal macrophages. J
Leukoc Biol 38:267–278.
16. Changelian PS, Jack RM, Collins LA, Fearon DT. 1985. PMA induces the
ligand-independent internalization of CR1 on human neutrophils. J
Immunol 134:1851–1858.
17. Cherukuri A, Cheng PC, Pierce SK. 2001. The role of the CD19/CD21
complex in B cell processing and presentation of complement-tagged
antigens. J Immunol 167:163–172. https://doi.org/10.4049/jimmunol.167
.1.163.
18. Del Nagro CJ, Kolla RV, Rickert RC. 2005. A critical role for complement
C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of
inﬂammatory arthritis. J Immunol 175:5379–5389. https://doi.org/10
.4049/jimmunol.175.8.5379.
19. Barrington RA, Schneider TJ, Pitcher LA, Mempel TR, Ma M, Barteneva NS,
Carroll MC. 2009. Uncoupling CD21 and CD19 of the B-cell coreceptor.
Proc Natl Acad Sci U S A 106:14490–14495. https://doi.org/10.1073/pnas
.0903477106.
20. Safar J, Wang W, Padgett MP, Ceroni M, Piccardo P, Zopf D, Gajdusek DC,
Gibbs CJ. 1990. Molecular mass, biochemical composition, and physico-
chemical behavior of the infectious form of the scrapie precursor protein
monomer. Proc Natl Acad Sci U S A 87:6373–6377. https://doi.org/10
.1073/pnas.87.16.6373.
21. Michel B, Meyerett-Reid C, Johnson T, Ferguson A, Wyckoff C, Pulford B,
Bender H, Avery A, Telling G, Dow S, Zabel MD. 2012. Incunabular
immunological events in prion trafﬁcking. Sci Rep 2:440. https://doi.org/
10.1038/srep00440.
22. Johnson TE, Michel BA, Meyerett C, Duffy A, Avery A, Dow S, Zabel MD.
2010. Monitoring immune cells trafﬁcking ﬂuorescent prion rods hours
after intraperitoneal infection. J Vis Exp https://doi.org/10.3791/2349.
23. Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS,
Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ,
Holers VM. 2001. Epitope mapping using the X-ray crystallographic
structure of complement receptor type 2 (CR2)/CD21: identiﬁcation of a
highly inhibitory monoclonal antibody that directly recognizes the
CR2-C3d interface. J Immunol 167:5758–5766. https://doi.org/10.4049/
jimmunol.167.10.5758.
24. Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. 2008. Molec-
ular basis of the interaction between complement receptor type 2
(CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol 82:
11217–11227. https://doi.org/10.1128/JVI.01673-08.
25. Kulik L, Chen K, Huber BT, Holers VM. 2011. Human complement recep-
tor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study
immunoregulatory effects of receptor antagonists. Mol Immunol 48:
883–894. https://doi.org/10.1016/j.molimm.2010.12.019.
26. Yoshida K, Van den Berg TK, Dijkstra CD. 1993. Two different mecha-
nisms of immune-complex trapping in the mouse spleen during im-
mune responses. Adv Exp Med Biol 329:377–382. https://doi.org/10
.1007/978-1-4615-2930-9_63.
27. Kinoshita T, Takeda J, Hong K, Kozono H, Sakai H, Inoue K. 1988.
Monoclonal antibodies to mouse complement receptor type 1 (CR1).
Their use in a distribution study showing that mouse erythrocytes and
platelets are CR1-negative. J Immunol 140:3066–3072.
28. Fischer MB, Roeckl C, Parizek P, Schwarz HP, Aguzzi A. 2000. Binding of
disease-associated prion protein to plasminogen. Nature 408:479–483.
https://doi.org/10.1038/35044100.
29. Hasegawa M, Fujimoto M, Poe JC, Steeber DA, Tedder TF. 2001. CD19
can regulate B lymphocyte signal transduction independent of comple-
ment activation. J Immunol 167:3190–3200. https://doi.org/10.4049/
jimmunol.167.6.3190.
30. Haas KM, Hasegawa M, Steeber DA, Poe JC, Zabel MD, Bock CB, Karp DR,
Briles DE, Weis JH, Tedder TF. 2002. Complement receptors CD21/35 link
innate and protective immunity during Streptococcus pneumoniae in-
fection by regulating IgG3 antibody responses. Immunity 17:713–723.
https://doi.org/10.1016/S1074-7613(02)00483-1.
31. von Poser-Klein C, Flechsig E, Hoffmann T, Schwarz P, Harms H, Bujdoso
R, Aguzzi A, Klein MA. 2008. Alteration of B-cell subsets enhances
neuroinvasion in mouse scrapie infection. J Virol 82:3791–3795. https://
doi.org/10.1128/JVI.02036-07.
32. Klein MA, Frigg R, Raeber AJ, Flechsig E, Hegyi I, Zinkernagel RM,
Weissmann C, Aguzzi A. 1998. PrP expression in B lymphocytes is not
required for prion neuroinvasion. Nat Med 4:1429–1433. https://doi.org/
10.1038/4022.
33. Montrasio F, Cozzio A, Flechsig E, Rossi D, Klein MA, Rülicke T, Raeber AJ,
Vosshenrich CA, Proft J, Aguzzi A, Weissmann C. 2001. B lymphocyte-
restricted expression of prion protein does not enable prion replication
in prion protein knockout mice. Proc Natl Acad Sci U S A 98:4034–4037.
https://doi.org/10.1073/pnas.051609398.
34. Montrasio F, Frigg R, Glatzel M, Klein MA, Mackay F, Aguzzi A, Weiss-
mann C. 2000. Impaired prion replication in spleens of mice lacking
functional follicular dendritic cells. Science 288:1257–1259. https://doi
.org/10.1126/science.288.5469.1257.
35. Prinz M, Montrasio F, Klein MA, Schwarz P, Priller J, Odermatt B, Pfeffer
K, Aguzzi A. 2002. Lymph nodal prion replication and neuroinvasion in
mice devoid of follicular dendritic cells. Proc Natl Acad Sci U S A
99:919–924. https://doi.org/10.1073/pnas.022626399.
Kane et al.
November/December 2017 Volume 2 Issue 6 e00493-17 msphere.asm.org 14
 o
n
 D
ecem
ber 28, 2017 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
36. Mackay F, Browning JL. 1998. Turning off follicular dendritic cells. Nature
395:26–27. https://doi.org/10.1038/25630.
37. Beringue V, Demoy M, Lasmézas CI, Gouritin B, Weingarten C, Deslys JP,
Andreux JP, Couvreur P, Dormont D. 2000. Role of spleen macrophages
in the clearance of scrapie agent early in pathogenesis. J Pathol 190:
495–502. https://doi.org/10.1002/(SICI)1096-9896(200003)190:4495::
AID-PATH5353.0.CO;2-T.
38. Chandler RL. 1961. Encephalopathy in mice produced by inoculation
with scrapie brain material. Lancet i:1378–1379. https://doi.org/10.1016/
S0140-6736(61)92008-6.
39. Saborio GP, Permanne B, Soto C. 2001. Sensitive detection of patholog-
ical prion protein by cyclic ampliﬁcation of protein misfolding. Nature
411:810–813. https://doi.org/10.1038/35081095.
40. Fischer M, Rülicke T, Raeber A, Sailer A, Moser M, Oesch B, Brandner S,
Aguzzi A, Weissmann C. 1996. Prion protein (PrP) with amino-proximal
deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO
J 15:1255–1264.
41. Pulford B, Spraker TR, Wyckoff AC, Meyerett C, Bender H, Ferguson A, Wyatt
B, Lockwood K, Powers J, Telling GC, Wild MA, Zabel MD. 2012. Detection of
PrPCWD in feces from naturally exposed Rocky Mountain elk (Cervus ela-
phus nelsoni) using protein misfolding cyclic ampliﬁcation. J Wildl Dis
48:425–434. https://doi.org/10.7589/0090-3558-48.2.425.
42. Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM,
Hannan JP. 2010. Delineation of the complement receptor type 2-C3d
complex by site-directed mutagenesis and molecular docking. J Mol Biol
404:697–710. https://doi.org/10.1016/j.jmb.2010.10.005.
Relative Impact of CD21/35 on Scrapie Pathogenesis
November/December 2017 Volume 2 Issue 6 e00493-17 msphere.asm.org 15
 o
n
 D
ecem
ber 28, 2017 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
